OncoMatch/Clinical Trials/NCT06727630
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Is NCT06727630 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies PRJ1-3024 for melanoma.
Treatment: PRJ1-3024 — This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic standard therapy
Patients who have progressed or relapsed after at least 1st-line systemic standard therapy
Cannot have received: hematopoietic progenitor kinase 1 (HPK1) inhibitor
Prior treatment with other hematopoietic progenitor kinase 1 (HPK1) inhibitors
Lab requirements
Blood counts
adequate hematologic parameters
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06727630 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hematopoietic progenitor kinase 1 (HPK1) inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages